Form D · Biotechnology
SNC Therapeutics, Inc.
Evanston, IL · CIK 0001966964
Offering snapshot reported Mar 8, 2023 · SEC filing
- Reported sold
- $250K Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $250K Reported outside-investor minimum
- First sale
- Feb 22, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 8, 2023 | Initial | $249,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-475270
Source: Form D, filed Mar 8, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Margarita Chavez | Director |
| Jeffrey A. Hubbell | Executive |
| Evan A. Scott | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1801 Maple Avenue Querrey In Qbation Lab, Suite 1400
Evanston, IL, 60201
Evanston, IL, 60201